The association between daily 500 mg calcium supplementation and lower pregnancy-induced hypertension risk in Bangladesh

Pregnancy-induced hypertension (PIH), defined as systolic blood pressure (sBP) > 140 mmHg or diastolic blood pressure (dBP) > 90 mmHg [1], is a major determinant of pre-eclampsia/eclampsia (PE/E). High BP is responsible for approximately 14% of global maternal deaths [2]. Pre-eclampsia affects an estimated 3.2% of all live births - a total of more than four million cases each year -nearly 1.8% of which are fatal [3‐5]. First described in 1980 [6], the inverse relationship between calcium supplementation during pregnancy and the risk of pregnancy-induced high blood pressure (BP) is well documented [7‐15].

Based on evidence from a meta-analysis of randomized controlled trials [16], the World Health Organization (WHO) recommends routine prenatal calcium supplementation of 1500 to 2000 mg daily beginning from 20th gestational week for all pregnant women, particularly those residing in low-calcium intake areas which are considered as high risk population [17]. It is notable that the overall calcium intake among the Bangladeshi population is low due to lack of calcium in the regular diet [18]. Although the WHO calcium regimen is endorsed by the government of Bangladesh, in reality the adoption rate has been lower due to bottlenecks such as poor compliance [19].

However, evidence of the impact of low-dose calcium supplementation (intake of 500 mg/d calcium tablet) on PIH is limited. A systematic review of the effects of low-dose calcium intake on pre-eclampsia has shown significant results [20]. The review included studies from both high-risk and low-risk populations and found a larger effect among high-risk populations accordingly. Since the data for this review came primarily from small studies, the authors called for larger trials to confirm the results.

Previous researchers have also suggested that a lower dose regimen may actually result in a higher cumulative calcium dose consumption through improved adherence [21]. High dose supplementation as recommended by WHO has not been widely adopted, likely because of practical impediments such as the size and number of units of conventional calcium tablets required to deliver the recommended daily dose (3 to 4 tablets). Furthermore, calcium tablets must be ingested separately from iron because of the negative impact of calcium on iron absorption. Therefore, building an evidence base on the effects of a low dose recommendation could have a tremendous impact in developing countries through saved resources. This study aims to assess the effects of different durations of low-dose calcium supplementation (500 mg daily) during pregnancy on the incidence of PIH.

Table 1 shows the distribution of demographic and lifestyle factors among the study population. A total of 57.4% women were aged between 20 and 29 years. Most of the women (99.1%) were housewives and 76.2% women had at least one child. 14.6% women had pacca/semi-pacca households and 46.8% were from poor households. Of the total 11,387 participants 9358 had four sBP measurements and 9356 had four dBP measurements; 10,376 had three sBP and 10,377 had three dBP measurements (Table 1).

Table 2 shows the calcium consumption during pregnancy by demographic and socio-economic variables. A total of 19.8% women consumed < 90 tablets (i.e. 500 mg/d calcium tablets for less than 3 months), while 66.0% consumed 90–179 tablets (i.e. 500 mg/d calcium tablets for 3–6 months) and 14.2% consumed 180 or more tablets (i.e. 500 mg/d calcium tablets for more than 6 months).Women between 20 and 29 years consumed more calcium tablets than women aged < 20 or > 30 years (P < 0.001). Low body-weight women (< 45 kg at enrollment) consumed a higher number of calcium tablets than higher body-weight women (P = 0.105). Women living in pacca/semi-pacca households consumed more tablets (P = 0.047), while consumption was similar between poor and non-poor households (P = 0.794). Moreover, calcium consumption largely depended on the number of ANC visits. Women who had four or more ANC check-ups consumed more calcium tablets than those who did not (P < 0.001). However, among all 11,387 study women, all had at least one ANC visit while 86% had four or more (Additional file 1: Table S1).

Table 3 shows the predicted mean sBPs and dBPs at baseline and four follow up visits by calcium intake categories. It also presents the absolute change in mean blood pressures from baseline to the last follow up visit. For both sBP and dBP, we observed a slower increase over time among those who consumed 500 mg/d calcium tablets for more than 6 months during the pregnancy period compared to those who consumed 500 mg/calcium tablets for fewer than 6 months.

We further compared the incidence of PIH after the 5th gestational month between calcium intake groups using log-binomial or modified Poisson regression model. Both unadjusted and adjusted models were implemented and results are presented in Table 4. The final model was adjusted by age and weight at enrollment, number of antenatal care visits, household asset, and administrative district. The overall incidence of PIH was 2.2% (250 out of 11,387). We found that women who consumed 500 mg/d calcium tablets for more than 6 months during the antenatal period had a significantly lower risk (46%) of developing hypertension than those who consumed 500 mg/d calcium tablets for fewer than 3 months (RR: 0.56, 95% CI: 0.33–0.93).

To our knowledge, this large-scale study is the first to examine the effectiveness of low dose supplemental calcium (500 mg) on the risk of PIH. We found that women had a 45% lower risk of developing hypertension when they took 500 mg/d calcium tablets for more than 6 months during pregnancy relative to those who consumed 500 mg/d calcium tablets for fewer than 3 months. The association of calcium consumption during pregnancy with decreased PIH is well documented in earlier studies [20, 29], yet the evidence of the use of low-dose calcium in a maternal health and nutrition intervention is scarce in low-income settings. We begin to fill this gap in the literature.

The World Health Organization (WHO) has recommended antenatal calcium supplementation of 1500–2000 mg daily for pregnant women with low dietary calcium intake who are thus at a higher risk for pre-eclampsia [16, 30]. However, a large proportion of Bangladeshi pregnant women are at high risk for multiple micronutrient deficiencies including antioxidants [18, 31]. While much research has focused on malnutrition among children, recent reports indicate a high prevalence of micronutrient deficiency among women as well [32]. Under these conditions, BRAC initiated the MNI program which includes the 500 mg daily calcium supplement.

Our study found that women living in the Rangpur and Lalmonirhat districts are at higher risk of PIH compared to Mymensingh district when adjusting for other factors including calcium intake. This result is consistent with the fact that Rangpur division has a higher prevalence calcium deficiency compared to the Dhaka division [18]. We also found that older age and higher weight significantly increased the risk of PIH which is consistent with findings from other studies [33].

Nevertheless, cross-sectional assessments of the association between calcium exposure and BP are limited by a) possible selection bias in capturing only individuals who have lived long enough to participate in the study, and b) weak detection of the latent effects of calcium exposure on BP. In contrast, longitudinal analyses mitigate some of these problems and may be a robust method for examining the effect of calcium consumption on blood pressure change over time.

In the present study, we found that 500 mg/d calcium tablets consumption for 180 days or more during pregnancy was associated with lower increase in mean BP. Also, the risk of hypertension was 45% lower among those women. While the observed reduction is significant, it does not point directly to clinical outcomes at the individual level. A majority of the women were lost from the sample before receiving ANC visits and calcium tablets, thus resulting in a type of survival bias. Subsequent loss at follow up resulted in missing outcome data. However, as our study population is very homogenous in nature, we expect very little bias from this loss. One major strength of our study is that any biases were minimized by combining individual calcium consumption and outcome data from registry. Moreover, loss at follow-up or missing data is a problem regardless of any possible assuring comparisons. We simply do not know how dropped observations could have affected risk ratios were they not missed. Moreover, most of the previous research which has been undertaken to assess the effectiveness of low-dose calcium was carried out among populations at high risk for calcium deficiency. In contrast, the present research was more robust in the sense that the data were collected from a general group of population, i.e. there was no particular low or high risk population.

The study is not without limitations. First, the conclusions are drawn in the absence of full-fledged randomized control trial. Due to lack of a true comparison group - especially the absence of a high dose supplementation group - we are unable to attribute the effectiveness with greater strength. We also did not collect the information through a questionnaire; rather information was extracted from the registrars of the SKs who were already working in the MNI areas. The registrars did not contain much relevant information which may influence both the calcium intake and blood pressure level among the women. Therefore, the study result should be used with caution as the information of few confounders such as body mass index, diabetes, family history of PIH and previous incident of PIH were missing [34, 35]. We are also unable to account for measurement errors as only one method of measurement was employed throughout the study duration.

Also, because the MNI initiative included the improvement of the dietary practices of pregnant and lactating mothers, the observed reduction in PIH could be due to an increase in calcium intake resulting from a generally improved diet. We did not assess the role of specific nutrients or nutritional intake in the present study. Future studies are needed to investigate whether the association of calcium intake and the rate of BP change differ by nutritional status.

The study demonstrated a positive association between low dose calcium supplementation and reduction in risk of BP among a large cohort of pregnant women who were homogeneous with respect to disease risk. The findings have several policy implications. These findings are consistent with other studies about reducing the risk of PIH which could have implications for current guidelines and their global implementation. Currently, the high cost of implementing the WHO recommended daily dose of calcium is regarded as prohibitive in low income settings. Moreover, this dose has not been widely adopted due to implementation bottlenecks, such as the difficulty of multiple (3–4 tablets) administrations per day. Therefore, the dilemma facing health policy-makers in these settings is often whether supplementation with a lower-dose would be better than no supplementation at all. The findings of this research are a step towards addressing the issue.

Currently, the introduction of calcium supplementation in maternal health program is strongly recommended by WHO especially among populations with low dietary intake of calcium. So farm knowledge is inadequate concerning adherence, motivation, costing and logistics to implement the scaling-up of public health program. Therefore, larger well-designed RCTs are still required to determine the efficacy of low dose calcium of 500 mg/d and to determine the optimal duration of supplementation. Future research should focus on the causal impact of these interventions as well as implementation research to find out optimal program strategies including cost-effectiveness.